On 1 MAY OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) reported ($0.59) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.50) by $0.09. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) net profit margin is -92.60% and weekly performance is 4.28%. On last trading day company shares ended up $3.90. Analysts mean target price for the company is $9.96. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) distance from 50-day simple moving average (SMA50) is -50.39%.
On 8 MAY Clovis Oncology Inc (NASDAQ:CLVS) announced first quarter operating results. Research and development expenses totaled $24.2 million for the first quarter of 2014. Revenue of $13.6 million pursuant to our collaboration and license agreement for lucitanib with Les Laboratoires Servier (Servier), earned as a result of the expiration of the opposition period of a lucitanib European patent. General and administrative expenses totaled $5.3 million for the first quarter of 2014. This increase is largely due to higher share-based compensation expense for employees engaged in general and administrative activities. Clovis Oncology Inc (NASDAQ:CLVS) shares advanced 5.25% in last trading session and ended the day on $51.55. CLVS return on assets is -22.30%. Clovis Oncology Inc (NASDAQ:CLVS) quarterly performance is -34.23%.
On 12 MAY TrovaGene Inc (NASDAQ:TROV) reported its financial results for the three months ended March 31, 2014.For the first quarter ended March 31, 2014, TrovaGene Inc (NASDAQ:TROV) reported a net loss of $3.2 million, or $0.17 per share, as compared to a net loss of $1.1 million, or $0.07 per share, for the three months ended March 31, 2013. The increase in net loss is primarily due to increased operating expenses and changes in the fair market value of derivative instruments during the first quarter of 2014 as compared to the prior year comparable period. TrovaGene Inc (NASDAQ:TROV) shares moved up 3.36% in last trading session and was closed at $3.69, while trading in range of $3.50 – $3.90. TrovaGene Inc (NASDAQ:TROV) year to date (YTD) performance is -35.71%.
On 23 MAY PTC Therapeutics, Inc. (NASDAQ:PTCT) announced that the company will provide an update on the re-examination of its marketing authorization application to the European Medicines Agency (EMA) for conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. PTC Therapeutics, Inc. (NASDAQ:PTCT) ended the last trading day at $23.25. Company weekly volatility is calculated as 18.84% and price to cash ratio as 2.84. PTC Therapeutics, Inc. (NASDAQ:PTCT) showed a positive weekly performance of 58.49%.
On 13 MAY Arca Biopharma Inc (NASDAQ:ABIO) reported first quarter results. Arca Biopharma Inc (NASDAQ:ABIO)’s R&D expense for the three months ended March 31, 2014 was $1.3 million compared to $181,000 for the corresponding period of 2013, an increase of approximately $1.1 million. Clinical expense increased approximately $563,000 for the three months ended March 31, 2014. Regulatory and manufacturing process costs increased $419,000 for the three months ended March 31, 2014. Arca Biopharma Inc (NASDAQ:ABIO) weekly performance is 8.82%. On last trading day company shares ended up $1.48. Analysts mean target price for the company is $3.75. Arca Biopharma Inc (NASDAQ:ABIO) distance from 50-day simple moving average (SMA50) is -11.05%.